comparemela.com

Latest Breaking News On - Lindy durrant - Page 1 : comparemela.com

Scancell receives approval to expand ModiFY cancer trial

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) to expand its ModiFY.

Lindy durrantHealthcare products regulatory agencyScancell holdingsProfessor lindy

Scancell : Interim Report 31st October 2023

CHIEF EXECUTIVE OFFICER S STATEMENT I am pleased to report the Group s interim results for the six-month period ended 31 October 2023. During the period, Scancell.

United kingdomLindy durrantScancell moditopeScancell avidimabScancell immunobodyCompany moditopeScancell holdingsRegistrar of companiesEuropean unionConvertible loan notesFinancial positionDerivative liabilitiesConsolidated profitConsolidated cash flow statementConvertible loanInterim financial statements

SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma

SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.

United kingdomLindy durrantUniversity of nottinghamAcademic department of clinical oncologyAcademic departmentClinical oncology

Scancell Holdings doses first patient with iSCIB1+

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), a developer of immunotherapies for cancer and infectious diseases, has reached a pivotal milestone in its.

Ls prasad kellatiLindy durrantScancell avidimabScancell holdingsRoyal preston

Investegate | Company Announcement

Investegate announcements from Scancell Attendance at Upcoming Conferences

United kingdomCity ofSamantha pastonNextgen multispecificsFreddy crossley emma earlNick adams harlandPoonam vagehlaNicholas moore samira essebiyeaJean michel cossMandeep sehmiMireille vankemmelbekeForam daveLindy durrantScancell holdingsWg partnersHead of business development

vimarsana © 2020. All Rights Reserved.